Skip to content

Study · Case report or series · n = 1 · 2024

2 results

Acute Pancreatitis Caused by Tirzepatide.

Mando N, Thomson E, Fowler M, Short L, Gillen N

Cureus19 Dec 2024Cited by 5 (Europe PMC)

PMID39834977 (opens in a new tab)PMCIDPMC11743417 (opens in a new tab)DOI10.7759/cureus.76007 (opens in a new tab)PepBankPUB-39834977
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Glucagon-like peptide-1 (GLP-1) receptor agonists, including tirzepatide (Mounjaro), are widely used to manage type 2 diabetes mellitus (T2DM) and obesity. While gastrointestinal side effects are common, acute pancreatitis remains a rare but significant complication. Limited evidence exists on the risks associated with switching between GLP-1 agonists, emphasizing the need for clinical awareness. We present a 59-year-old male with T2DM, hyperlipidemia, and hypertension, who was recently transitioned from semaglutide (Ozempic) to tirzepatide (Mounjaro). He presented with acute epigastric pain, nausea, and vomiting two days after initiating tirzepatide. Laboratory findings revealed elevated lipase levels (847 U/L), leukocytosis, and diagnostic imaging confirming acute pancreatitis with other causes ruled out. Supportive care improved symptoms initially, but the clinical course was complicated by fevers prompting repeat imaging, revealing worsening pancreatitis with colonic involvement and pleural effusion. The patient was treated with empiric antibiotics and supportive measures, resulting in resolution of symptoms. Tirzepatide was discontinued, with a follow-up arranged for glycemic management. Acute pancreatitis is a rare but documented adverse effect of GLP-1 agonists, with limited cases reported in the literature. Switching between GLP-1 agonists may increase the risk of adverse effects, especially if appropriate dose titration protocols are not followed. This case highlights the recognition of acute pancreatitis as a potential adverse effect of GLP-1 agonists when initiating or transitioning GLP-1 therapies and following titration protocols to help avoid this complication. GLP-1 agonists, including tirzepatide, offer significant therapeutic benefits for T2DM and obesity but carry risks of rare adverse effects like acute pancreatitis. Greater awareness, careful dose adjustments, and vigilant monitoring are essential to optimizing patient safety. Further research is needed to elucidate the safety profile of switching between GLP-1 agonists to guide clinical practice and improve patient outcomes.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 59-year-old man with type 2 diabetes switched from semaglutide, acute pancreatitis with raised lipase (847 U/L) was confirmed two days after starting tirzepatide.

    In plain wordsIn one man with type 2 diabetes, acute pancreatitis appeared two days after he started tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseAcute pancreatitis after starting tirzepatide
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Lipase
    847 U/L
    patient at presentation

    Source sentences

    Summary
    Laboratory findings revealed elevated lipase levels (847 U/L), leukocytosis, and diagnostic imaging confirming acute pancreatitis with other causes ruled out.
    2 context sentences
    Summary · context
    He presented with acute epigastric pain, nausea, and vomiting two days after initiating tirzepatide.
    Summary · context
    We present a 59-year-old male with T2DM, hyperlipidemia, and hypertension, who was recently transitioned from semaglutide (Ozempic) to tirzepatide (Mounjaro).
  2. 02HumanCase report or seriesSafety outcome

    In the same patient, the course was complicated by fevers and repeat imaging showed worsening pancreatitis with colonic involvement and pleural effusion.

    In plain wordsIn this one man, imaging later showed the pancreatitis had worsened, with colon involvement and fluid around the lung.

    Peptide
    Tirzepatide
    Outcome
    IncreaseWorsening pancreatitis with colonic involvement and pleural effusion
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Supportive care improved symptoms initially, but the clinical course was complicated by fevers prompting repeat imaging, revealing worsening pancreatitis with colonic involvement and pleural effusion.
    1 context sentence
    Summary · context
    We present a 59-year-old male with T2DM, hyperlipidemia, and hypertension, who was recently transitioned from semaglutide (Ozempic) to tirzepatide (Mounjaro).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.